AMT Announces Presentations During the 11th Annual Meeting of the ASGT
28/05/2008 21:49
PR Newswire
AMSTERDAM, May 28 /PRNewswire/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field
of human gene therapy, announced today a series of presentations during the
11th Annual Meeting of the American Society of Gene Therapy in Boston,
including a presentation on the pivotal clinical trial with its lead product
AMT-011 on May 29.
About Amsterdam Molecular Therapeutics
AMT has a unique gene therapy platform that to date appears to
circumvent many if not all of the obstacles that have prevented gene therapy
from becoming a mainstay of clinical medicine. Using adeno-associated viral
(AAV) vectors as the delivery vehicle of choice for therapeutic genes, the
company has been able to design and validate what is probably the first
stable and scalable AAV production platform. As such, AMT's proprietary
platform holds tremendous promise for thousands of rare (orphan) diseases
that are caused by one faulty gene. AMT currently has a product pipeline with
six products at different stages of development.
Certain statements in this press release are "forward-looking
statements" including those that refer to management's plans and expectations
for future operations, prospects and financial condition. Words such as
"strategy," "expects," "plans," "anticipates," "believes," "will,"
"continues," "estimates," "intends," "projects," "goals," "targets" and other
words of similar meaning are intended to identify such forward-looking
statements. Such statements are based on the current expectations of the
management of Amsterdam Molecular Therapeutics only. Undue reliance should
not be placed on these statements because, by their nature, they are subject
to known and unknown risks and can be affected by factors that are beyond the
control of AMT. Actual results could differ materially from current
expectations due to a number of factors and uncertainties affecting AMT's
business, including, but not limited to, the timely commencement and success
of AMT's clinical trials and research endeavors, delays in receiving U.S.
Food and Drug Administration or other regulatory approvals (i.e. EMEA, Health
Canada), market acceptance of AMT's products, effectiveness of AMT's
marketing and sales efforts, development of competing therapies and/or
technologies, the terms of any future strategic alliances, the need for
additional capital, the inability to obtain, or meet, conditions imposed for
required governmental and regulatory approvals and consents. AMT expressly
disclaims any intent or obligation to update these forward-looking statements
except as required by law. For a more detailed description of the risk
factors and uncertainties affecting AMT, refer to the prospectus of AMT's
initial public offering on June 20, 2007, and AMT's public announcements made
from time to time.
http://www.amtbiopharma.com
PRN NLD
For information: André Verwei, CFO, , +31-20-566-5686, a.verwei@amtbiopharma.com; Rob Janssen, Director Corporate, Communications & Investor Relations, +31-20-566-7509, r.janssen@amtbiopharma.com
-